Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.

Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z.

J Med Chem. 2014 Jun 26;57(12):5112-28. doi: 10.1021/jm4017762. Epub 2014 Jun 10.

PMID:
24915291
[PubMed - in process]
2.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids MS, Brown JR.

Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51.

PMID:
24941982
[PubMed - in process]
3.

Ibrutinib for B cell malignancies.

Novero A, Ravella PM, Chen Y, Dous G, Liu D.

Exp Hematol Oncol. 2014 Jan 28;3(1):4. doi: 10.1186/2162-3619-3-4.

PMID:
24472371
[PubMed]
Free PMC Article
4.

Ibrutinib.

Schwarzbich MA, Witzens-Harig M.

Recent Results Cancer Res. 2014;201:259-67. doi: 10.1007/978-3-642-54490-3_17.

PMID:
24756799
[PubMed - in process]
5.

Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.

Burger JA.

Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. doi: 10.1007/s11899-013-0188-8.

PMID:
24357428
[PubMed - in process]
6.

Different sensitivity of germinal center B cell-like diffuse large B cell lymphoma cells towards ibrutinib treatment.

Zheng X, Ding N, Song Y, Feng L, Zhu J.

Cancer Cell Int. 2014 Apr 3;14(1):32. doi: 10.1186/1475-2867-14-32.

PMID:
24693884
[PubMed]
Free PMC Article
7.

Bruton's TK inhibitors: structural insights and evolution of clinical candidates.

Xing L, Huang A.

Future Med Chem. 2014 Apr;6(6):675-95. doi: 10.4155/fmc.14.24.

PMID:
24895895
[PubMed - in process]
8.

Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.

Ponader S, Burger JA.

J Clin Oncol. 2014 Jun 10;32(17):1830-9. doi: 10.1200/JCO.2013.53.1046. Epub 2014 Apr 28.

PMID:
24778403
[PubMed - in process]
9.

The promising impact of ibrutinib, a Bruton's tyrosine kinase inhibitor, for the management of lymphoid malignancies.

Bhatt V, Alejandro L, Michael A, Ganetsky A.

Pharmacotherapy. 2014 Mar;34(3):303-14. doi: 10.1002/phar.1366. Epub 2013 Dec 12.

PMID:
24338680
[PubMed - in process]
10.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

PMID:
24311722
[PubMed - indexed for MEDLINE]
11.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

PMID:
24869598
[PubMed - indexed for MEDLINE]
12.

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Brown JR.

Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9. Review.

PMID:
23296407
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

PMID:
24307721
[PubMed - indexed for MEDLINE]
14.

Single cell imaging of Bruton's tyrosine kinase using an irreversible inhibitor.

Turetsky A, Kim E, Kohler RH, Miller MA, Weissleder R.

Sci Rep. 2014 Apr 24;4:4782. doi: 10.1038/srep04782.

PMID:
24759210
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.

Shi Q, Tebben A, Dyckman AJ, Li H, Liu C, Lin J, Spergel S, Burke JR, McIntyre KW, Olini GC, Strnad J, Surti N, Muckelbauer JK, Chang C, An Y, Cheng L, Ruan Q, Leftheris K, Carter PH, Tino J, De Lucca GV.

Bioorg Med Chem Lett. 2014 May 1;24(9):2206-11. doi: 10.1016/j.bmcl.2014.02.075. Epub 2014 Mar 13.

PMID:
24685542
[PubMed - in process]
16.

Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].

Mahajan S, Ghosh S, Sudbeck EA, Zheng Y, Downs S, Hupke M, Uckun FM.

J Biol Chem. 1999 Apr 2;274(14):9587-99.

PMID:
10092645
[PubMed - indexed for MEDLINE]
Free Article
17.

Synergistic induction of apoptosis by combination of BTK and dual mTORC1/2 inhibitors in diffuse large B cell lymphoma.

Ezell SA, Mayo M, Bihani T, Tepsuporn S, Wang S, Passino M, Grosskurth SE, Collins M, Parmentier J, Reimer C, Byth KF.

Oncotarget. 2014 Jul 15;5(13):4990-5001.

PMID:
24970801
[PubMed - in process]
Free Article
18.

Novel Bruton's tyrosine kinase inhibitors currently in development.

D'Cruz OJ, Uckun FM.

Onco Targets Ther. 2013;6:161-76. doi: 10.2147/OTT.S33732. Epub 2013 Mar 6.

PMID:
23493945
[PubMed]
Free PMC Article
19.

Activation loop phosphorylation modulates Bruton's tyrosine kinase (Btk) kinase domain activity.

Lin L, Czerwinski R, Kelleher K, Siegel MM, Wu P, Kriz R, Aulabaugh A, Stahl M.

Biochemistry. 2009 Mar 10;48(9):2021-32. doi: 10.1021/bi8019756.

PMID:
19206206
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk